BACKGROUND: Worldwide, the incidence of thick melanoma has not declined, and the nodular melanoma (NM) subtype accounts for nearly 40% of newly diagnosed thick melanoma. To assess differences between patients with thin (<or=2.00 mm) and thick (>or=2.01 mm) nodular melanoma, the authors evaluated factors such as demographics, melanoma detection patterns, tumor visibility, and physician screening for NM alone and compared clinical presentation and anatomic location of NM with superficial spreading melanoma (SSM). METHODS: The authors used data from a large population-based study of Queensland (Australia) residents diagnosed with melanoma. Queensland residents aged 20 to 75 years with histologically confirmed first primary invasive cutaneous melanoma were eligible for the study, and all questionnaires were conducted by telephone (response rate, 77.9%). RESULTS: During this 4-year period, 369 patients with nodular melanoma were interviewed, of whom 56.7% were diagnosed with tumors <or=2.00 mm. Men, older individuals, and those who had not been screened by a physician in the past 3 years were more likely to have nodular tumors of greater thickness. Thickest nodular melanoma (4 mm+) was also most common in persons who had not been screened by a physician within the past 3 years (odds ratio, 3.75; 95% confidence interval, 1.47-9.59). Forty-six percent of patients with thin nodular melanoma (<or=2.00 mm) reported a change in color, compared with 64% of patients with thin SSM and 26% of patients with thick nodular melanoma (>2.00 mm). CONCLUSIONS: Awareness of factors related to earlier detection of potentially fatal nodular melanomas, including the benefits of a physician examination, should be useful in enhancing public and professional education strategies. Particular awareness of clinical warning signs associated with thin nodular melanoma should allow for more prompt diagnosis and treatment of this subtype. Copyright (c) 2009 American Cancer Society.
BACKGROUND: Worldwide, the incidence of thick melanoma has not declined, and the nodular melanoma (NM) subtype accounts for nearly 40% of newly diagnosed thick melanoma. To assess differences between patients with thin (<or=2.00 mm) and thick (>or=2.01 mm) nodular melanoma, the authors evaluated factors such as demographics, melanoma detection patterns, tumor visibility, and physician screening for NM alone and compared clinical presentation and anatomic location of NM with superficial spreading melanoma (SSM). METHODS: The authors used data from a large population-based study of Queensland (Australia) residents diagnosed with melanoma. Queensland residents aged 20 to 75 years with histologically confirmed first primary invasive cutaneous melanoma were eligible for the study, and all questionnaires were conducted by telephone (response rate, 77.9%). RESULTS: During this 4-year period, 369 patients with nodular melanoma were interviewed, of whom 56.7% were diagnosed with tumors <or=2.00 mm. Men, older individuals, and those who had not been screened by a physician in the past 3 years were more likely to have nodular tumors of greater thickness. Thickest nodular melanoma (4 mm+) was also most common in persons who had not been screened by a physician within the past 3 years (odds ratio, 3.75; 95% confidence interval, 1.47-9.59). Forty-six percent of patients with thin nodular melanoma (<or=2.00 mm) reported a change in color, compared with 64% of patients with thin SSM and 26% of patients with thick nodular melanoma (>2.00 mm). CONCLUSIONS: Awareness of factors related to earlier detection of potentially fatal nodular melanomas, including the benefits of a physician examination, should be useful in enhancing public and professional education strategies. Particular awareness of clinical warning signs associated with thin nodular melanoma should allow for more prompt diagnosis and treatment of this subtype. Copyright (c) 2009 American Cancer Society.
Authors: Constance S Harrell Shreckengost; Marvi Tariq; Clara R Farley; Chao Zhang; Keith A Delman; Ragini R Kudchadkar; Michael C Lowe Journal: Ann Surg Oncol Date: 2021-03-14 Impact factor: 5.344
Authors: Laura Poliseno; Adele Haimovic; Miguel F Segura; Douglas Hanniford; Paul J Christos; Farbod Darvishian; Jinhua Wang; Richard L Shapiro; Anna C Pavlick; Russell S Berman; Eva Hernando; Jiri Zavadil; Iman Osman Journal: J Invest Dermatol Date: 2012-05-03 Impact factor: 8.551
Authors: Clara Curiel-Lewandrowski; Caroline C Kim; Susan M Swetter; Suephy C Chen; Allan C Halpern; John M Kirkwood; Sancy A Leachman; Ashfaq A Marghoob; Michael E Ming; James M Grichnik Journal: J Invest Dermatol Date: 2012-02-16 Impact factor: 8.551
Authors: Amel Salhi; Joshua A Farhadian; Keith M Giles; Eleazar Vega-Saenz de Miera; Ines P Silva; Caitlin Bourque; Karen Yeh; Sagar Chhangawala; Jinhua Wang; Fei Ye; David Y Zhang; Eva Hernando-Monge; Yariv Houvras; Iman Osman Journal: Am J Pathol Date: 2015-01-08 Impact factor: 4.307
Authors: Loraine A Escobedo; Ashley Crew; Ariana Eginli; David Peng; Michael R Cousineau; Myles Cockburn Journal: Health Place Date: 2017-04-06 Impact factor: 4.078
Authors: Clio Dessinioti; Alan C Geller; Aravella Stergiopoulou; Susan M Swetter; Eszter Baltas; Jonathan E Mayer; Timothy M Johnson; John Talaganis; Myrto Trakatelli; Dimitrios Tsoutsos; Gerasimos Tsourouflis; Alexander J Stratigos Journal: JAMA Dermatol Date: 2018-05-01 Impact factor: 10.282